Trade Calcimedica Inc - CALC CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.6864 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 6.0468 |
| Open* | 5.4889 |
| 1-Year Change* | 319% |
| Day's Range* | 5.341 - 6.2951 |
| 52 wk Range | 4.88-20.44 |
| Average Volume (10 days) | 13.44K |
| Average Volume (3 months) | 74.39K |
| Market Cap | 9.95M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 1.57M |
| Revenue | N/A |
| EPS | -23.21 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | May 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 5.5768 | 0.2301 | 4.30% | 5.3467 | 6.5507 | 5.0805 |
| Mar 21, 2023 | 6.0468 | 1.2311 | 25.56% | 4.8157 | 6.1436 | 4.7284 |
| Mar 20, 2023 | 5.3451 | -0.6469 | -10.80% | 5.9920 | 5.9920 | 5.0602 |
| Mar 17, 2023 | 0.4280 | -0.0478 | -10.05% | 0.4758 | 0.4763 | 0.4273 |
| Mar 16, 2023 | 0.4761 | -0.0195 | -3.93% | 0.4956 | 0.4958 | 0.4580 |
| Mar 15, 2023 | 0.4937 | 0.0277 | 5.94% | 0.4660 | 0.4969 | 0.4660 |
| Mar 14, 2023 | 0.4762 | -0.0145 | -2.95% | 0.4907 | 0.4957 | 0.4737 |
| Mar 13, 2023 | 0.4960 | -0.0093 | -1.84% | 0.5053 | 0.5151 | 0.4859 |
| Mar 10, 2023 | 0.5041 | 0.0008 | 0.16% | 0.5033 | 0.5120 | 0.4857 |
| Mar 9, 2023 | 0.5346 | -0.0034 | -0.63% | 0.5380 | 0.5637 | 0.5164 |
| Mar 8, 2023 | 0.5638 | 0.0408 | 7.80% | 0.5230 | 0.5647 | 0.5230 |
| Mar 7, 2023 | 0.5637 | 0.0395 | 7.54% | 0.5242 | 0.5823 | 0.5242 |
| Mar 6, 2023 | 0.5556 | -0.0273 | -4.68% | 0.5829 | 0.5829 | 0.5537 |
| Mar 3, 2023 | 0.5476 | 0.0429 | 8.50% | 0.5047 | 0.5588 | 0.5047 |
| Mar 2, 2023 | 0.5345 | 0.0292 | 5.78% | 0.5053 | 0.5347 | 0.5053 |
| Mar 1, 2023 | 0.5390 | 0.0045 | 0.84% | 0.5345 | 0.5832 | 0.5339 |
| Feb 28, 2023 | 0.5285 | -0.0056 | -1.05% | 0.5341 | 0.5347 | 0.5179 |
| Feb 27, 2023 | 0.5536 | -0.0004 | -0.07% | 0.5540 | 0.5543 | 0.5343 |
| Feb 24, 2023 | 0.5439 | -0.0390 | -6.69% | 0.5829 | 0.5975 | 0.5273 |
| Feb 23, 2023 | 0.5915 | 0.0065 | 1.11% | 0.5850 | 0.6124 | 0.5837 |
Calcimedica Inc Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 |
| Total Operating Expense | 35.947 | 29.832 | 37.502 | 28.57 |
| Selling/General/Admin. Expenses, Total | 17.044 | 8.87 | 6.922 | 5.599 |
| Research & Development | 18.903 | 20.962 | 30.58 | 22.971 |
| Operating Income | -35.947 | -29.832 | -37.502 | -28.57 |
| Interest Income (Expense), Net Non-Operating | 0.126 | 0.143 | 0.393 | 0.192 |
| Other, Net | 0 | 2.158 | 0.072 | 0 |
| Net Income Before Taxes | -35.821 | -27.531 | -37.037 | -28.378 |
| Net Income After Taxes | -35.821 | -27.531 | -37.037 | -28.378 |
| Net Income Before Extra. Items | -35.821 | -27.531 | -37.037 | -28.378 |
| Net Income | -35.821 | -27.531 | -37.037 | -28.378 |
| Total Adjustments to Net Income | 0 | -7.189 | -7.055 | -4.317 |
| Income Available to Common Excl. Extra. Items | -35.821 | -34.72 | -44.092 | -32.695 |
| Income Available to Common Incl. Extra. Items | -35.821 | -34.72 | -44.092 | -32.695 |
| Diluted Net Income | -35.821 | -34.72 | -44.092 | -32.695 |
| Diluted Weighted Average Shares | 21.1993 | 21.044 | 19.1556 | 19.1556 |
| Diluted EPS Excluding Extraordinary Items | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Diluted Normalized EPS | -1.68973 | -1.64988 | -2.30178 | -1.70681 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 10.184 | 8.701 | 8.017 | 7.741 | 11.488 |
| Selling/General/Admin. Expenses, Total | 4.127 | 4.433 | 3.996 | 3.575 | 5.04 |
| Research & Development | 6.057 | 4.268 | 4.021 | 4.166 | 6.448 |
| Operating Income | -10.184 | -8.701 | -8.017 | -7.741 | -11.488 |
| Interest Income (Expense), Net Non-Operating | 0.035 | 0.026 | 0.028 | 0.033 | 0.039 |
| Other, Net | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Net Income After Taxes | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Net Income Before Extra. Items | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Net Income | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
| Income Available to Common Excl. Extra. Items | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Income Available to Common Incl. Extra. Items | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Diluted Net Income | -10.149 | -8.675 | -7.989 | -7.708 | -11.449 |
| Diluted Weighted Average Shares | 21.3578 | 21.3376 | 21.2875 | 21.1487 | 21.0204 |
| Diluted EPS Excluding Extraordinary Items | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.47519 | -0.40656 | -0.37529 | -0.36447 | -0.54466 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 67.078 | 99.24 | 36.271 | 13.445 |
| Cash and Short Term Investments | 63.67 | 95.033 | 35.956 | 12.834 |
| Cash & Equivalents | 13.364 | 33.418 | 15.87 | 12.834 |
| Short Term Investments | 50.306 | 61.615 | 20.086 | 0 |
| Prepaid Expenses | 2.034 | 4.207 | 0.315 | 0.611 |
| Total Assets | 69.088 | 101.794 | 40.66 | 17.813 |
| Property/Plant/Equipment, Total - Net | 1.981 | 1.946 | 1.975 | 1.515 |
| Property/Plant/Equipment, Total - Gross | 3.634 | 3.08 | 2.714 | 1.958 |
| Accumulated Depreciation, Total | -1.653 | -1.134 | -0.739 | -0.443 |
| Other Long Term Assets, Total | 0.029 | 0.608 | 2.414 | 2.853 |
| Total Current Liabilities | 4.057 | 6.997 | 12.251 | 5.794 |
| Accounts Payable | 0.527 | 2.513 | 4.636 | 2.523 |
| Accrued Expenses | 2.582 | 3.658 | 4.377 | 2.924 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.948 | 0.826 | 3.238 | 0.347 |
| Total Liabilities | 4.065 | 7.008 | 12.251 | 5.794 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 65.023 | 94.786 | 28.409 | 12.019 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 131.363 | 78.811 |
| Common Stock | 0.002 | 0.002 | 0 | 0 |
| Additional Paid-In Capital | 234.225 | 228.155 | 2.879 | 2.007 |
| Retained Earnings (Accumulated Deficit) | -169.188 | -133.367 | -105.836 | -68.799 |
| Unrealized Gain (Loss) | -0.016 | -0.004 | 0.003 | 0 |
| Total Liabilities & Shareholders’ Equity | 69.088 | 101.794 | 40.66 | 17.813 |
| Total Common Shares Outstanding | 21.3578 | 20.9793 | 19.1556 | 19.1556 |
| Other Liabilities, Total | 0.008 | 0.011 | ||
| Total Preferred Shares Outstanding | 0 | |||
| Total Receivables, Net | 0.021 | |||
| Other Current Assets, Total | 1.353 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 58.222 | 67.078 | 74.496 | 76.051 | 88.821 |
| Cash and Short Term Investments | 55.28 | 63.67 | 72.554 | 73.586 | 85.688 |
| Cash & Equivalents | 8.36 | 13.364 | 11.452 | 7.864 | 10.589 |
| Short Term Investments | 46.92 | 50.306 | 61.102 | 65.722 | 75.099 |
| Prepaid Expenses | 2.942 | 3.408 | 1.942 | 2.465 | 3.133 |
| Total Assets | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
| Property/Plant/Equipment, Total - Net | 2.335 | 1.981 | 2.113 | 2.006 | 2.002 |
| Other Long Term Assets, Total | 0.029 | 0.029 | 0.029 | 0.136 | 0.029 |
| Total Current Liabilities | 4.228 | 4.057 | 4.49 | 4.141 | 6.278 |
| Accounts Payable | 0.541 | 0.527 | 2.066 | 2.101 | 1.956 |
| Accrued Expenses | 2.216 | 2.582 | 1.729 | 1.543 | 3.378 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.471 | 0.948 | 0.695 | 0.497 | 0.944 |
| Total Liabilities | 4.33 | 4.065 | 4.502 | 4.154 | 6.29 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.102 | 0.008 | 0.012 | 0.013 | 0.012 |
| Total Equity | 56.256 | 65.023 | 72.136 | 78.667 | 84.562 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 235.767 | 234.225 | 232.641 | 231.183 | 229.376 |
| Retained Earnings (Accumulated Deficit) | -179.337 | -169.188 | -160.513 | -152.524 | -144.816 |
| Unrealized Gain (Loss) | -0.176 | -0.016 | 0.006 | 0.006 | 0 |
| Total Liabilities & Shareholders’ Equity | 60.586 | 69.088 | 76.638 | 82.821 | 90.852 |
| Total Common Shares Outstanding | 21.3578 | 21.3578 | 21.3166 | 21.2847 | 21.0559 |
| Long Term Investments | 4.628 | ||||
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -35.821 | -27.531 | -37.037 | -28.378 |
| Cash From Operating Activities | -31.5 | -32.064 | -31.215 | -28.216 |
| Cash From Operating Activities | 0.519 | 0.395 | 0.303 | 0.175 |
| Non-Cash Items | 5.433 | -0.369 | 0.598 | 0.366 |
| Changes in Working Capital | -1.631 | -4.559 | 4.921 | -0.379 |
| Cash From Investing Activities | 10.751 | -42.56 | -20.62 | -1.461 |
| Capital Expenditures | -0.488 | -1.023 | -0.605 | -1.461 |
| Other Investing Cash Flow Items, Total | 11.239 | -41.537 | -20.015 | 0 |
| Cash From Financing Activities | 0.695 | 92.172 | 54.871 | 42.019 |
| Financing Cash Flow Items | 0 | -4.16 | -0.045 | 0 |
| Issuance (Retirement) of Stock, Net | 0.695 | 96.332 | 54.916 | 42.019 |
| Net Change in Cash | -20.054 | 17.548 | 3.036 | 12.342 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.149 | -35.821 | -27.146 | -19.157 | -11.449 |
| Cash From Operating Activities | -6.524 | -31.5 | -22.545 | -17.045 | -9.264 |
| Cash From Operating Activities | 0.122 | 0.519 | 0.383 | 0.247 | 0.118 |
| Non-Cash Items | 3.81 | 5.433 | 3.946 | 2.508 | 1.169 |
| Changes in Working Capital | -0.307 | -1.631 | 0.272 | -0.643 | 0.898 |
| Cash From Investing Activities | 1.52 | 10.751 | -0.035 | -9.096 | -13.657 |
| Capital Expenditures | 0 | -0.488 | -0.484 | -0.304 | -0.136 |
| Other Investing Cash Flow Items, Total | 1.52 | 11.239 | 0.449 | -8.792 | -13.521 |
| Cash From Financing Activities | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0 | 0.695 | 0.614 | 0.587 | 0.092 |
| Net Change in Cash | -5.004 | -20.054 | -21.966 | -25.554 | -22.829 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Graybug Vision, Inc. Company profile
About Graybug Vision Inc
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The Company's lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD) and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Graybug Vision Inc revenues was not reported. Net loss applicable to common stockholders increased 3% to $35.8M. Higher net loss reflects Labor & Related Expenses in SGA increase from $3.3M to $7.7M (expense), Stock-based Compensation in SGA increase from $1.4M to $4.2M (expense), Fair Value Adjustments on Other Assets decrease from $2.2M (income) to $0K.
| Industry: | Bio Therapeutic Drugs |
274 Redwood Shores Parkway
P.O. Box 144
REDWOOD CITY
CALIFORNIA 94065
US
Income Statement
- Annual
- Quarterly
News
China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023
World refined copper market in 103,000 tonne surplus in January –ICSG
March 22 (Reuters) - The world's refined copper market had a 103,000 tonne surplus in January, compared with a 10,000 tonnes surplus the previous month, the International Copper Study Group (ICSG) said in its latest monthly bulletin.
15:10, 22 March 2023
Fitness chains add financial muscle as more Americans hit the gym
By Deborah Mary Sophia
15:07, 22 March 2023
House Republicans subpoena labor authorities in Starbucks union dispute - WSJ
March 22 (Reuters) - A Congressional committee issued a subpoena to the National Labor Relations Board, alleging that employees of the labor body mishandled union elections at Starbucks Corp SBUX.O cafes in ways that favored unionizing workers, the Wall Street Journal reported on Wednesday, citing a letter.
15:06, 22 March 2023
China Evergrande publishes plan to restructure $22.7 bln offshore debt
HONG KONG, March 22 (Reuters) - China Evergrande Group 3333.HK on Wednesday published long-awaited plans to restructure its $22.7 billion of offshore debt.
15:02, 22 March 2023
Crop merchant Louis Dreyfus to step up spending after earnings boost
Writes through with details, quote
14:59, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com